Overview

Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study is to determine if regular and daily repeated application of the ciclopirox lotion to vulva will make the precancerous lesion(s) shrink or even disappear.
Phase:
N/A
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Treatments:
Antineoplastic Agents
Ciclopirox
Criteria
Inclusion Criteria:

- Patients between the ages 18 and 75 years.

- Patients may be carriers of the Human Immunodeficiency Virus (HIV).

- Patients must have been diagnosed with precancerous lesion(s) of the vulva by tissue
sampling (biopsy-proven vulvar intraepithelial neoplasia grade II or III)

- Patients must be able to come to University Hospital for their initial appointment in
Gynecologic Oncology Clinic, and for the eight follow-up visits in that Clinic
required by the protocol.

Exclusion Criteria:

- Pregnant or patients who are breast feeding a baby.

- Patients who have been diagnosed with a vaginal yeast infection.

- Patients who have undergone prior surgery for precancerous lesion(s) of the vulva.